Tafamidis Tied to 74% Lower Death Risk in Matched Real-World Heart Amyloidosis Cohort
A matched real-world cohort analysis found that patients with transthyretin amyloid cardiomyopathy treated with tafamidis had a 74% lower risk ...
Tag: ATTR-CM
Research report: Phenotypic Considerations for Tafamidis Use in a Real-World Cohort of Older Patients with Transthyretin Amyloid Cardiomyopathy
A pooled real-world analysis of 1,924 patients with transthyretin amyloid cardiomyopathy treated with tafamidis found that outcomes in patients aged ...
Real-World Data Suggest Acoramidis Outperforms Tafamidis in Heart Amyloidosis
A retrospective US claims analysis found that newly treated ATTR-CM patients starting acoramidis had significantly lower risks of diuretic intensification ...
POPULAR NEWS
-
Global Financing Facility falls short on adolescent health funding in three country case studies
-
Prostate Cancer Detection Rose After MRI Arrived, But a Single-Centre Study Says the Reason Stays Unclear
-
Midday Sunlight Yields Smaller Copper Nanoparticles With Stronger Antibacterial Activity
-
Never-Smoker COPD Shows Stronger Lung Function Gains from Salbutamol and Glycopyrronium